ArticleARYA atherosclerosis2026
The use and the cost of inpatient diagnostic and therapeutic procedures for cardiovascular diseases in public hospitals of Isfahan, Iran.
Article in ARYA atherosclerosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular diseases (CVDs) are the most important cause of mortality and disability worldwide, causing substantial personal, social, and economic problems. This study determined the use and Cost of inpatient diagnostic and therapeutic CVD procedures in Isfahan from 2019 to 2021.
methodsThis descriptive study covered a three-year period (2019-2021). Data were gathered from the Health Information System of two public hospitals that carried out these procedures (Chamran and Khorshid hospitals) in Isfahan, Iran. A list of procedures was carefully chosen according to experts' opinions, for which the use and cost of these procedures were extracted.
resultsCoronary angiography demonstrated the highest annual average use (47.65%), while mitral valve repair showed the lowest (0.06%). The highest annual average total cost was seen in angioplasty (617,425,750,917 IRR), while the lowest was seen in mitral valve repair (2,375,305,232 IRR). Regarding cost per procedure, VSD surgery (409,107,479 IRR) had the highest annual average cost, while the lowest was seen in coronary angiography (56,340,938 IRR). A consistent upward trend in cost per procedure (in IRR) was observed across all procedures during the study period.
conclusionThe majority of cardiovascular procedure costs are attributable to diagnosing and treating ischemic heart disease (IHD). Consequently, the increasing prevalence of CVDs particularly IHD coupled with the use of advanced technologies, imposes a significant financial burden on the healthcare system. This underscores the critical need for policy actions focused on lifestyle modification and primary prevention. Such measures are essential to curb rising costs and ensure healthcare system sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.